398 related articles for article (PubMed ID: 28283780)
1. Metabolic carbonyl reduction of anthracyclines - role in cardiotoxicity and cancer resistance. Reducing enzymes as putative targets for novel cardioprotective and chemosensitizing agents.
Piska K; Koczurkiewicz P; Bucki A; Wójcik-Pszczoła K; Kołaczkowski M; Pękala E
Invest New Drugs; 2017 Jun; 35(3):375-385. PubMed ID: 28283780
[TBL] [Abstract][Full Text] [Related]
2. In Silico and In Vitro Assessment of Carbonyl Reductase 1 Inhibition Using ASP9521-A Potent Aldo-Keto Reductase 1C3 Inhibitor with the Potential to Support Anticancer Therapy Using Anthracycline Antibiotics.
Jamrozik M; Piska K; Bucki A; Koczurkiewicz-Adamczyk P; Sapa M; Władyka B; Pękala E; Kołaczkowski M
Molecules; 2023 Apr; 28(9):. PubMed ID: 37175180
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of human anthracycline reductases by emodin - A possible remedy for anthracycline resistance.
Hintzpeter J; Seliger JM; Hofman J; Martin HJ; Wsol V; Maser E
Toxicol Appl Pharmacol; 2016 Feb; 293():21-9. PubMed ID: 26773812
[TBL] [Abstract][Full Text] [Related]
4. Are cardioprotective effects of NO-releasing drug molsidomine translatable to chronic anthracycline cardiotoxicity settings?
Lenčová-Popelová O; Jansová H; Jirkovský E; Bureš J; Jirkovská-Vávrová A; Mazurová Y; Reimerová P; Vostatková L; Adamcová M; Hroch M; Pokorná Z; Kovaříková P; Šimůnek T; Štěrba M
Toxicology; 2016 Nov; 372():52-63. PubMed ID: 27816693
[TBL] [Abstract][Full Text] [Related]
5. Flavonoids as protectors against doxorubicin cardiotoxicity: role of iron chelation, antioxidant activity and inhibition of carbonyl reductase.
Kaiserová H; Simůnek T; van der Vijgh WJ; Bast A; Kvasnicková E
Biochim Biophys Acta; 2007 Sep; 1772(9):1065-74. PubMed ID: 17572073
[TBL] [Abstract][Full Text] [Related]
6. In vitro evaluation of the reductive carbonyl idarubicin metabolism to evaluate inhibitors of the formation of cardiotoxic idarubicinol via carbonyl and aldo-keto reductases.
Bajraktari-Sylejmani G; Oster JS; Burhenne J; Haefeli WE; Sauter M; Weiss J
Arch Toxicol; 2024 Mar; 98(3):807-820. PubMed ID: 38175295
[TBL] [Abstract][Full Text] [Related]
7. [Cardiooncology: Current Aspects of Prevention of Anthracycline Toxicity].
Vasyuk YA; Shkolnik EL; Nesterov VV; Shkolnik LD; Varlan GV
Kardiologiia; 2016 Dec; 56(12):72-79. PubMed ID: 28290807
[TBL] [Abstract][Full Text] [Related]
8. Cardioprotective effects of inorganic nitrate/nitrite in chronic anthracycline cardiotoxicity: Comparison with dexrazoxane.
Lenčová-Popelová O; Jirkovský E; Jansová H; Jirkovská-Vávrová A; Vostatková-Tichotová L; Mazurová Y; Adamcová M; Chládek J; Hroch M; Pokorná Z; Geršl V; Šimůnek T; Štěrba M
J Mol Cell Cardiol; 2016 Feb; 91():92-103. PubMed ID: 26724189
[TBL] [Abstract][Full Text] [Related]
9. Anthracycline secondary alcohol metabolite formation in human or rabbit heart: biochemical aspects and pharmacologic implications.
Mordente A; Minotti G; Martorana GE; Silvestrini A; Giardina B; Meucci E
Biochem Pharmacol; 2003 Sep; 66(6):989-98. PubMed ID: 12963485
[TBL] [Abstract][Full Text] [Related]
10. Single-nucleotide polymorphisms in aldo-keto and carbonyl reductase genes are not associated with acute cardiotoxicity after daunorubicin chemotherapy.
Lubieniecka JM; Liu J; Heffner D; Graham J; Reid R; Hogge D; Grigliatti TA; Riggs WK
Cancer Epidemiol Biomarkers Prev; 2012 Nov; 21(11):2118-20. PubMed ID: 23001242
[TBL] [Abstract][Full Text] [Related]
11. Phase I and II agents in cancer therapy: I. Anthracyclines and related compounds.
Wadler S; Fuks JZ; Wiernik PH
J Clin Pharmacol; 1986; 26(7):491-509. PubMed ID: 2944917
[TBL] [Abstract][Full Text] [Related]
12. Derivation of Anthracycline and Anthraquinone Equivalence Ratios to Doxorubicin for Late-Onset Cardiotoxicity.
Feijen EAM; Leisenring WM; Stratton KL; Ness KK; van der Pal HJH; van Dalen EC; Armstrong GT; Aune GJ; Green DM; Hudson MM; Loonen J; Oeffinger KC; Robison LL; Yasui Y; Kremer LCM; Chow EJ
JAMA Oncol; 2019 Jun; 5(6):864-871. PubMed ID: 30703192
[TBL] [Abstract][Full Text] [Related]
13. Anthracycline resistance mediated by reductive metabolism in cancer cells: the role of aldo-keto reductase 1C3.
Hofman J; Malcekova B; Skarka A; Novotna E; Wsol V
Toxicol Appl Pharmacol; 2014 Aug; 278(3):238-48. PubMed ID: 24832494
[TBL] [Abstract][Full Text] [Related]
14. Interactions of antileukemic drugs with daunorubicin reductases: could reductases affect the clinical efficacy of daunorubicin chemoregimens?
Novotná E; Morell A; Büküm N; Hofman J; Danielisová P; Wsól V
Arch Toxicol; 2020 Sep; 94(9):3059-3068. PubMed ID: 32588086
[TBL] [Abstract][Full Text] [Related]
15. AKR1B10 induces cell resistance to daunorubicin and idarubicin by reducing C13 ketonic group.
Zhong L; Shen H; Huang C; Jing H; Cao D
Toxicol Appl Pharmacol; 2011 Aug; 255(1):40-7. PubMed ID: 21640744
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of aldo-keto reductases by phenobarbital alters metabolism, pharmacokinetics and toxicity of doxorubicin in rats.
Behnia K; Boroujerdi M
J Pharm Pharmacol; 1999 Nov; 51(11):1275-82. PubMed ID: 10632085
[TBL] [Abstract][Full Text] [Related]
17. Anthracycline metabolism and toxicity in human myocardium: comparisons between doxorubicin, epirubicin, and a novel disaccharide analogue with a reduced level of formation and [4Fe-4S] reactivity of its secondary alcohol metabolite.
Minotti G; Licata S; Saponiero A; Menna P; Calafiore AM; Di Giammarco G; Liberi G; Animati F; Cipollone A; Manzini S; Maggi CA
Chem Res Toxicol; 2000 Dec; 13(12):1336-41. PubMed ID: 11123976
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in the prevention of anthracycline cardiotoxicity in childhood.
Iarussi D; Indolfi P; Casale F; Coppolino P; Tedesco MA; Di Tullio MT
Curr Med Chem; 2001 Nov; 8(13):1649-60. PubMed ID: 11562284
[TBL] [Abstract][Full Text] [Related]
19. Anthracycline-induced cardiotoxicity - are we about to clear this hurdle?
Dempke WCM; Zielinski R; Winkler C; Silberman S; Reuther S; Priebe W
Eur J Cancer; 2023 May; 185():94-104. PubMed ID: 36966697
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Anthracycline Alcohol Metabolite Formation in Human Heart Cytosol: A Potential Role for Several Promising Drugs.
Mordente A; Silvestrini A; Martorana GE; Tavian D; Meucci E
Drug Metab Dispos; 2015 Nov; 43(11):1691-701. PubMed ID: 26265744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
